ArticleFrontiers in immunology2025
Identification of hub genes in congenital hypothyroidism and construction of the associated immune regulatory network.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The absence of universal diagnosis and treatment recommendations for congenital hypothyroidism (CH) has led to suboptimal diagnostic and therapeutic outcomes. This study aimed to provide immunologically relevant evidence for the diagnosis and treatment of CH. Methods: Datasets related to CH were selected. Differentially expressed genes were screened, followed by enrichment analysis, weighted gene coexpression network analysis (WGCNA), protein-protein interaction analysis, and machine learning for the identification of hub genes. The reliability of these hub genes was verified through least absolute shrinkage and selection operator (LASSO) regression, box plot comparison, and receiver operating characteristic (ROC) curve analysis. Through gene set enrichment analysis (GSEA) of coexpressed genes, the common pathways of the hub genes and the inflammatory factors involved were identified. Immunoinfiltration analysis was carried out to verify the immunological correlation. Inflammatory factors and immune cells were screened by batch Mendelian randomization. Finally, the reliability of the hub genes, their relationships with inflammatory factors, and their impacts on cell function and the synthesis of free thyroxine (FT4) were validated through real-time quantitative polymerase chain reaction (RT-qPCR), enzyme-linked immunosorbent assay (ELISA), and cell proliferation experiments. Results: Multiomics analysis confirmed that APP, DDB1, MRPS5, and MRPL33 were hub genes with low expression levels in CH. These genes negatively regulated IL-2, and subsequently, through the STAT5 and MTORC1 pathways, they positively regulated (CD27 on IgD- CD38+ B cells) and (CD27 on switched memory B cells)/CD244 and negatively regulated (CD33dim HLA DR+ CD11b- Absolute Count)/IL-18 and (CD28+ CD4-CD8- T-cell %T cell)/OPG, promoting the progression of CH. Increasing the expression levels of these hub genes could increase the activity of thyroid cells and promote the synthesis of FT4 through the abovementioned pathways. Conclusions: APP, DDB1, MRPS5, and MRPL33 regulate the expression of IL-2, act on relevant immune cell subtypes through the STAT5 and MTORC1 pathways, negatively regulate IL-18 and OPG, and positively regulate CD244, thereby influencing the activity of thyroid cells and the synthesis of FT4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.